Pemvidutide

Status

In trials. Investigational. Altimmune aligned a Phase 3 obesity program with FDA in November 2024, then pivoted its lead development to liver disease: a Phase 3 MASH trial (PERFORMA) began enrolling in August 2026, and the compound holds FDA Breakthrough Therapy Designation in MASH. It is not FDA-approved, and no approval elsewhere is listed in this entry's sources.

What it is

A balanced GLP-1/glucagon dual agonist — the same receptor pairing as survodutide, with the glucagon arm aimed at liver fat and energy expenditure rather than appetite alone.

What published research measured

The 48-week phase 2 obesity trial (MOMENTUM) reported 15.6% mean weight loss on its highest dose — a company topline announcement from 2023, not a peer-reviewed publication. Phase 2b results in MASH supported the pivot into Phase 3 for liver disease, and a phase 2 trial in alcohol use disorder is also reading out. The obesity program sits ready but unfilled.

Source

Altimmune announcements (MOMENTUM 2023; PERFORMA, August 2026); FDA Breakthrough Therapy Designation in MASH

Sources

No linked primary source is on file for this entry yet.

Educational use only, never medical advice. No doses.